The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
Subject has provided informed consent prior to initiation of any study-procedures
Age from 18 to 75 years old at the time of signing the informed consent
Histologically or cytologically confirmed solid tumors
At least one measurable lesion was identified per RECIST 1.1
Subjects with active central nervous system (CNS) metastasis.
Subjects with a history of malignant tumors within 5 years prior to the first dose
Subjects with uncontrolled cancer pain.
Subjects with severe cardiovascular disease.